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Radboud UMC, Nijmegen, The NetherlandsAbstractCandida auris is an emerging multidrug resistant yeast that causes
nosocomial fungaemia and deep-seated infections. Notably, the
emergence of this yeast is alarming as it exhibits resistance to
azoles, amphotericin B and caspofungin, which may lead to
clinical failure in patients. The multigene phylogeny and ampliﬁed
fragment length polymorphism typing methods report the
C. auris population as clonal. Here, using whole genome
sequencing analysis, we decipher for the ﬁrst time that C. auris
strains from four Indian hospitals were highly related, suggesting
clonal transmission. Further, all C. auris isolates originated from
cases of fungaemia and were resistant to ﬂuconazole
(MIC >64 mg/L).
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This is an open access artiIntroductionCandida auris is a multidrug-resistant yeast ﬁrst described in
2009 as a species closely resembling Candida haemulonii [1–3].
The emergence of C. auris as an agent of nosocomial fungaemia
and deep-tissue infections is alarming as this yeast is notorious
for multidrug resistance [4–6]. Antifungal susceptibility pat-
terns in various studies showed resistance to azoles, ampho-
tericin B and caspofungin that may lead to clinical failure in
patients [3,7]. Many laboratories worldwide rely on phenotypic
commercial automated systems for routine identiﬁcation of
yeasts, which may lead to misidentiﬁcation of C. auris as
C. haemulonii, so underestimating the spread of this yeast [7].
Recently, C. auris genetic and proteomic diversity analyses using
matrix-assisted laser desorption/ionization time-of-ﬂight mass
spectrometry (MALDI-TOF MS), ampliﬁed fragment length
polymorphism and multi-gene phylogeny in Indian, South Afri-
can, Japanese, Korean and Brazilian isolates demonstrated
geographically speciﬁc clustering [8,9]. In this study we conﬁrm
for the ﬁrst time using whole genome sequencing that C. auris
strains exhibit high clonality in different hospitals in India.Materials and methodsCandida auris isolates
Five C. auris strains from candidaemia patients in four hospitals
in India were sequenced for whole genome analysis [3,8]. Their
origin and clinical details are presented in Table 1. The isolates
were identiﬁed by MALDI-TOF and sequencing of internal
transcribed spacer and D1/D2 regions.
IlluminaMiSeq sequence determination
GenomicDNAwas extracted using a column-basedmethodwith
a QIAamp DNA minikit (Qiagen, Hilden, Germany) and pro-
cessed using the Nextera XT DNA protocol (Illumina, Inc., San
Diego, CA, USA) to generate sequencing-ready libraries. The
genome was sequenced using an Illumina MiSeq platform with
MiSeq v3 protocol (Paired-End, 300 × 2). Equal volumes of
normalized libraries were combined, diluted and heat denatured
and the resulting FASTQ ﬁles were imported into CLCGENOMICS
WORKBENCH for analysis. The genomes were assembled by the
combination of VELVET v1.2.0 [10], SSPACE 2.0 and GAP-FILLER
v1.10 [11,12]. Repetitive sequences were masked using REPEAT-
MASKER v4.0.5 (http://www.repeatmasker.org), followed by ab
initio gene prediction using GENEMARK-ES 2.0 [13]. Next, rRNA
and tRNA were predicted with RNAMMER and tRNASCAN-SE
v1.21 respectively [14,15]. Single-nucleotide polymorphism wasNew Microbes and New Infect 2016; 13: 77–82
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TABLE 1. Clinical details and in vitro antifungal susceptibility proﬁle of Candida auris (n[ 5) isolates
Isolate
Specimen/ year
of isolation Hospital Age /Sex Diagnosis Risk factors Therapy Outcome
Drugsa (MIC, mg/L)
ITC VRC ISA POS AMB CFG MFG AFG FLU FC
VPCI 669/P/12 Blood/ 2012 Hospital 1,
New Delhi
74/M Jejunal perforation,
peritonitis,
septicaemia, MODS,
DM
CVC, Broad-spectrum
antibiotics, Surgery
within 30 days,
Intensive care,
Antifungals within
30 days, Indwelling
urinary catheter
CFG (loading dose
of 70 mg, then
50 mg daily) for
2 weeks
Died 14 days
after presentation
0.125 0.125 0.125 0.06 0.5 0.25 0.125 0.5 64 0.125
VPCI 692/P/12 Blood/ 2012 Hospital 1,
New Delhi
3 days/F PT, TEF, ICH sepsis Neutropenia,
Broad-spectrum
antibiotics, Intensive
care, Indwelling urinary
catheter
CFG (loading dose
of 70 mg, then
50 mg daily) for
5 days
Died 8 days
after admission
0.125 0.25 0.06 0.125 1 0.25 0.125 0.125 64 0.125
VPCI 479/P/13 Blood/ 2013 Hospital 2,
Kochi
48/F RHD CVC, Broad-spectrum
antibiotics, Parenteral
nutrition, Intensive care,
Antifungals within 30 days,
Indwelling urinary catheter
FLU (400 mg once
daily) for 7 days
Died 1 month
after admission
0.125 0.5 0.125 0.06 0.25 0.5 0.06 0.125 >64 0.5
VPCI 510/P/14 Blood/ 2014 Hospital 3,
New Delhi
37/M Chronic liver disease
with decompensation
Broad-spectrum antibiotics,
Antifungals within 30 days.
FLU( 400 mg once
daily) for 7 days
Not followed 0.5 16 0.25 0.25 4 0.5 0.125 0.5 64 0.25
VPCI 550/P/14 Blood/ 2014 Hospital 4,
New Delhi
62/M Hepato biliary carcinoma Broad-spectrum antibiotics,
Antifungal within 30 days,
Urinary catheter, Intensive
care, Chemotherapy
FLU Died 0.25 2 0.25 0.015 1 8 >8 >8 >64 >64
MODS, multi organ dysfunction syndrome; DM, diabetes mellitus; PT, pre-term; TEF, tracheo-oesophageal ﬁstula; ICH, intracranial haemorrhage; RHD, rheumatic heart disease; CVC, central venous catheter.
aITC, itraconazole; VRC, voriconazole; ISA, isavuconazole; POSA, posaconazole; AMB, amphotericin B; CFG, caspofungin; MFG, micafungin; AFG, anidulafungin; FLU, ﬂuconazole; FC, ﬂucytosine.
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NMNI Sharma et al. Multidrug resistant Candida auris 79detected using UNIFIED GENOTYPER from the Genome Analysis
Toolkit package [16]. The functional annotation was performed
using the Clusters of Orthologous Groups of proteins (COGs)
database [17]. To determine that C. auris belongs to the CUG
Candida clade, a webserver Bagheera [18] was used to identify
CUG codon usage in C. auris genomes.
Average nucleotide identity and phylogenetic analysis
of C. auris
Average nucleotide identity (ANI) was calculated using the JSPE-
CIES package [19] using MUMMER (ANIm). Five Candida auris
genomes (contigs) were compared with other publically available
Candida species genomes (n = 8) detailed in Table 2 by aligning the
sequences using progressiveMAUVEwith the default settings [20].
The strip Subset ‘Locally Collinear Blocks’ script was used to
extract core blocks, creating core alignments longer than 500 bp
including all 13 genomes. A core genome alignment in XMFA
format was obtained which was converted into FASTA format
using a PerlScript (https://github.com/lskatz/lskScripts). A phylo-
genetic network was constructed using SPLITSTREE based on
concatenated alignment of the core genes [21].
Antifungal susceptibility testing and antifungal
resistance genes analysis
Antifungal susceptibility testing of C. auris (n = 5) was carried
out using the CLSI broth microdilution method, following the
M27-A3 guidelines [22]. In addition, a control group of 20
Candida albicans isolates originating from invasive and superﬁcial
candidiasis and stocked in the culture collection of Vallabhbhai
Patel Chest Institute (VPCI) were subjected to antifungal sus-
ceptibility testing. Newly revised epidemiological cut-off MIC
values for C. albicans for ﬂuconazole (>0.5 mg/L), itraconazole
(>0.12 mg/L), voriconazole (>0.03 mg/L), posaconazole
(>0.06 mg/L), amphotericin B (>2 mg/L), ﬂucytosine (>0.5 mg/
L), anidulafungin (>0.12 mg/L), caspofungin (>0.12 mg/L) and
micafungin (>0.03 mg/L) were used for comparison of C. auris
MIC data [23]. The contigs from all the ﬁve C. auris strains were
aligned and screened for the presence of ERG (ERG3 and
ERG11) and FKS (FKS1, FKS2 and FKS3) genes and compared
with the C. albicans and Candida glabrata ERG and FKS genes.
Also, a solitary echinocandin-resistant C. auris isolate (VPCI
550/P/15, Table 1) was subjected to ampliﬁcation and
sequencing of the FKS1 and FKS2 genes to analyse the muta-
tions similar to those reported in C. glabrata [7].es
ul
ts
o
f
V
P
C
I
47
9/
P
/1
10
0
99
.8
5
99
.8
4
99
.8
4
99
.8
5
84
.0
7
83
.6
1
i )
85
.8
0)
85
.9
5
)
83
.5
2
84
.8
6
84
.0
7
84
.2
5ResultsT
A
B
L
E
2.
R
S
tr
ai
ns
V
PC
I4
79
/P
/1
3
V
PC
I6
69
/P
/1
2
V
PC
I6
92
/P
/1
2
V
PC
I5
10
/P
/1
4
V
PC
I5
50
/P
/1
4
C.
du
bl
in
ie
ns
is
(C
D
36
)
C.
al
bi
ca
ns
(W
O
-1
an
d
SC
53
14
)
C.
gu
ille
rm
on
di
(A
T
C
C
62
60
C.
lu
sit
an
ia
e
(A
T
C
C
42
72
C.
tr
op
ica
lis
(M
Y
A
-3
40
4
S.
ce
re
vis
ia
e
(S
28
8C
)
C.
pa
ra
ps
ilo
sis
(3
17
)
C.
gl
ab
ra
ta
(C
BS
13
8)The internal transcribed spacer and D1/D2 regions of the ri-
bosomal DNA sequences of C. auris isolates showed 99%© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 13, 77–82
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
80 New Microbes and New Infections, Volume 13 Number C, September 2016 NMNIhomology with the type C. auris isolates in GenBank. In all
candidaemia cases the most common risk factor was the
concomitant use of broad-spectrum antibiotics, intensive care
unit stay and presence of indwelling urinary catheter. Other
risk factors included parenteral nutrition and use of antifungals
in three patients (Table 1). Four patients who developed
breakthrough fungaemia had a fatal outcome.
Phylogenetic analysis
The assembled C. auris genome is diploid, comprising 12.3 Mb
with a G+C content of 44.8%. A total of 6675 coding sequences
among all the isolates were found with one 5.8S rRNA, 184
tRNA and 3262 repetitive elements. A phylogeny based on the
concatenated sequences of 136 conserved core genes of the
C. auris genomes (n = 5) and other Candida species (n = 8) con-
ﬁrms that the C. auris isolates are more similar to each other
than to other Candida species analysed (Fig. 1a). Remarkably, the
genome of all C. auris isolates analysed was highly related with
only 0.2% variation observed among their genomes (Table 2).
Among all sequenced C. auris isolates, single-nucleotide poly-
morphism differences ranging from 3048 to 4330 were
observed. ANI calculated for the C. auris isolates is consistently
above 99% (Table 2). In contrast the low ANI value (<95%)FIG. 1. (a) Phylogenetic tree based on 136 core/conserved genes of the Cand
Candida auris genome based on Clusters of Orthologous Groups of proteins
© 2016 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Micr
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceamong C. auris and other Candida species suggested its diver-
gence from the Candida genomes listed (Fig. 1a, Table 2). Among
the eight Candida species aligned with C. auris, the highest ANI
value (85.9%–86.4%) was observed for Candida lusitaniae. Also,
the functional annotation data suggest 40% of the C. auris pro-
teins to be orthologous to C. lusitaniae with most of them
assigned as hypothetical or functionally uncharacterized.
Functional annotation of C. auris
Although a major proportion of the C. auris genome remains
uncharacterized, a large number of proteins possessed trans-
porter along with binding and catalytic activity involved in cellular
and metabolic processes followed by proteins involved in signal
transduction (Fig. 1b). Candida auris shares virulence traits com-
mon to C. albicans. The presence of orthologues including ion
transporters, amino acid and metabolite transporters, oligopep-
tide transporters, secreted proteinases, lipases, phospholipases,
adhesins, secreted aspartyl proteases, mannosyl transferases,
MADS-box (for Minichromosome Maintenance1, Agamous,
Deﬁciens and SerumResponse Factor) and STE (Serine/threonine
enzyme)-related proteins in C. auris genomewere observedwhen
compared with C. albicans as a reference genome (Fig. 1b). The
above-mentioned gene classes may contribute to virulenceida auris isolates and other Candida species. (b) Functional annotation of
(COG) database classiﬁcation.
obiology and Infectious Diseases, NMNI, 13, 77–82
nses/by-nc-nd/4.0/).
NMNI Sharma et al. Multidrug resistant Candida auris 81acquisition in C. auris isolates. The codon usage analysis in C. auris
appears to be more similar and overlapping with C. lusitaniae than
with any otherCandida species, indicating that C. auris is part of the
CUG clade. This similarity has been supported by the phyloge-
netic and functional data.
Antifungal susceptibility patterns and analysis of
antifungal resistance genes
The in vitro susceptibility data of C. auris (n = 5) is presented in
Table 1. All isolates were resistant to ﬂuconazole, one each was
resistant to voriconazole and amphotericin B and the other
isolate was resistant to voriconazole, ﬂucytosine and echino-
candins. The PCR targeting FKS1 and FKS2 genes of a solitary
echinocandin-resistant C. auris isolate (VPCI 550/P/15) generated
amplicons of 391 bp and 460 bp, respectively. Echinocandin-
resistant C. auris did not reveal any mutation in the hot spot
regions previously reported for caspofungin-resistant C. glabrata.
In contrast to C. auris, all C. albicans isolates were found to be
highly susceptible to all azoles including itraconazole (MIC50,
0.03 mg/L; MIC90, 0.03 mg/L); voriconazole (MIC50, 0.03 mg/L;
MIC90, 0.03 mg/L); posaconazole (MIC50, 0.015 mg/L; MIC90,
0.015 mg/L) and amphotericin B (MIC50, 0.5 mg/L; MIC90,
0.5 mg/L). The alignment of the C. auris contigs with C. albicans
and C. glabrata ERG and FKS genes revealed that ERG3, ERG11,
FKS1, FKS2 and FKS3 genes were present as a single copy in the
C. auris genome. ERG and FKS genes of C. auris exhibited
78%–85% similarity with those of C. albicans and C. glabrata.
Furthermore, the C. auris genome when analysed with
C. albicans and Saccharomyces cerevisiae revealed that a signiﬁ-
cant portion of its genome encodes ABC and MFS transporter
family along with drug transporters. A number of zinc cluster
transcription factor orthologues such as TAC1 (29% similarity
with C. albicans) and protein kinases, which may contribute to
the acquisition of drug resistance were observed (Fig. 1b). The
protein kinases such as protein kinase A, HOG1 have been
reported to be activated on perceiving stress thereby regulating
the stress signalling pathways to enhance tolerance of patho-
genic fungi to various fungicides [24].
Mating locus analysis
Mining of the de novo assembly of C. auris sequence reads the
presence of MATα locus, similar to Naumovozyma castellii CBS
4309, in all the C. auris strains investigated. However, the MATa
gene was absent in all the isolates in the present study.DiscussionThe application of whole genome sequencing conﬁrms for the
ﬁrst time that C. auris strains in Indian settings are highly clonal,© 2016 The Author(s). Published by Elsevier Ltd on behal
This is an open access articsuggesting the possibility of a common source of origin or a
phenomenon of their recent differentiation. It is noteworthy to
mention that ANI analysis showed C. auris strains exhibiting a
highly divergent relationship with other clinically signiﬁcant
Candida species namely C. albicans, C. tropicalis, C. parapsilosis and
C. glabrata. However, the genome of C. aurismay be more closely
related to C. haemulonii with whom C. auris is commonly mis-
identiﬁed using phenotypic methods but whose genome is not
yet sequenced. Future studies analysing the whole genome
sequencing of other related Candida species might provide more
insight about their similarity with C. auris. The lack of information
on the ecological niche of C. auris hampers the understanding of
its divergence from other Candida species. Further, all the strains
of C. auris analysed in the present study were recovered from ﬁve
individual patients in four hospitals located 50–2000 km apart
and at a different time period. However, irrespective of the
variability in the above parameters all strains exhibited low ge-
netic diversity. Also, all the C. auris strains exhibitedMATαmating
locus and its presence was also validated by gene-speciﬁc PCR.
Further experiments analysing themating locus in a large number
of C. auris isolates will determine the true sexual status of this
pathogen. Furthermore, the antifungal resistance proﬁle of the
isolates was variable but uniformly showed the presence of ABC
and MFS transporters, which may explain the multidrug resis-
tance. It is also possible that the undiscerning use of antifungals
has resulted in its emergence as a successful multidrug-resistant
pathogen. Overall our study provides the ﬁrst comparative
analysis of C. auris genomes using whole genome sequencing and
highlights clonal expansion of C. auris isolates in India.Conﬂict of interestJFM received grants from Astellas, Basilea and Merck. He has
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